Abstract
Herpes Simplex Virus (HSV) has a number of advantages as a gene delivery vector, particularly for the nervous system. Thus, it naturally establishes asymptomatic latent infections of neuronal cells. Moreover, it is readily grown in culture to high titre and has a large genome so allowing it to be used to deliver multiple or very large genes. Considerable progress has been made in effectively disabling the virus so that it does not damage the cells it infects but can still deliver an inserted gene effectively. In addition, it is now possible to obtain long-term expression of the transgene in the nervous system, using regulatory elements derived from the latency-associated transcript of the virus. As well as its use in the nervous system, the virus has also been used to successfully deliver genes to a variety of other cell types, including peripheral blood mononuclear cells and cardiac myocytes within the intact heart. In particular, its ability to deliver genes effectively to replicating cancer cells and to dendritic cells offers considerable potential for the use of this virus in cancer therapy.
Current Gene Therapy
Title: Herpes Simplex Virus Vectors for Gene Delivery to a Variety of Different Cell Types
Volume: 2 Issue: 4
Author(s): David S. Latchman
Affiliation:
Abstract: Herpes Simplex Virus (HSV) has a number of advantages as a gene delivery vector, particularly for the nervous system. Thus, it naturally establishes asymptomatic latent infections of neuronal cells. Moreover, it is readily grown in culture to high titre and has a large genome so allowing it to be used to deliver multiple or very large genes. Considerable progress has been made in effectively disabling the virus so that it does not damage the cells it infects but can still deliver an inserted gene effectively. In addition, it is now possible to obtain long-term expression of the transgene in the nervous system, using regulatory elements derived from the latency-associated transcript of the virus. As well as its use in the nervous system, the virus has also been used to successfully deliver genes to a variety of other cell types, including peripheral blood mononuclear cells and cardiac myocytes within the intact heart. In particular, its ability to deliver genes effectively to replicating cancer cells and to dendritic cells offers considerable potential for the use of this virus in cancer therapy.
Export Options
About this article
Cite this article as:
Latchman S. David, Herpes Simplex Virus Vectors for Gene Delivery to a Variety of Different Cell Types, Current Gene Therapy 2002; 2 (4) . https://dx.doi.org/10.2174/1566523023347698
DOI https://dx.doi.org/10.2174/1566523023347698 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Polymorphisms of Human N-Acetyltransferases and Cancer Risk
Current Drug Metabolism Thalidomide as an Antiangiogenic Drug in the Treatment of Multiple Myeloma
Letters in Drug Design & Discovery Molecular Probing and Imaging of Histone Deacetylase Inhibitors in Cancer Treatment
Anti-Cancer Agents in Medicinal Chemistry One-Compound-Multi-Target: Combination Prospect of Natural Compounds with Thrombolytic Therapy in Acute Ischemic Stroke
Current Neuropharmacology Combining Bevacizumab with Radiation or Chemoradiation for Solid Tumors: A Review of the Scientific Rationale, and Clinical Trials
Current Angiogenesis (Discontinued) Emerging Adenoviral Vectors for Stable Correction of Genetic Disorders
Current Gene Therapy Nampt/Visfatin/PBEF: A Functionally Multi-faceted Protein with a Pivotal Role in Malignant Tumors
Current Pharmaceutical Design Regulation of Autophagy by Sphingolipids
Anti-Cancer Agents in Medicinal Chemistry Role of ncRNAs in Development, Diagnosis and Treatment of Human Cancer
Recent Patents on Anti-Cancer Drug Discovery CD133+ Glioblastoma Stem-Like Cells Induce Vascular Mimicry in Vivo
Current Neurovascular Research Gold Nanoparticles in Cancer Therapy: Efficacy, Biodistribution, and Toxicity
Current Pharmaceutical Design In Vitro Models of the Blood-Brain Barrier: When to Use Which?
Current Medicinal Chemistry - Central Nervous System Agents Hybrid Compounds Containing Carvacrol Scaffold: <i>In Vitro</i> Antibacterial and Cytotoxicity Evaluation
Recent Advances in Anti-Infective Drug Discovery Induction of Abscopal Anti-Tumor Immunity and Immunogenic Tumor Cell Death by Ionizing Irradiation - Implications for Cancer Therapies
Current Medicinal Chemistry Long Non-coding RNA AFAP1-AS1 Facilitates Prostate Cancer Progression by Regulating miR-15b/IGF1R Axis
Current Pharmaceutical Design Aluminum Vaccine Adjuvants: Are they Safe?
Current Medicinal Chemistry Stem Cells as Delivery Vehicles for Oncolytic Adenoviral Virotherapy
Current Gene Therapy Mitochondrial Dysfunction and Lipid Homeostasis
Current Drug Metabolism Exploiting Metabolic Differences in Glioma Therapy
Current Drug Discovery Technologies Protein Kinases as Drug Targets in Human and Animal Diseases
Current Enzyme Inhibition